Literature DB >> 11013243

Tyrosine 220 in the 5th transmembrane domain of the neuromedin B receptor is critical for the high selectivity of the peptoid antagonist PD168368.

K Tokita1, S J Hocart, T Katsuno, S A Mantey, D H Coy, R T Jensen.   

Abstract

Peptoid antagonists are increasingly being described for G protein-coupled receptors; however, little is known about the molecular basis of their binding. Recently, the peptoid PD168368 was found to be a potent selective neuromedin B receptor (NMBR) antagonist. To investigate the molecular basis for its selectivity for the NMBR over the closely related receptor for gastrin-releasing peptide (GRPR), we used a chimeric receptor approach and a site-directed mutagenesis approach. Mutated receptors were transiently expressed in Balb 3T3. The extracellular domains of the NMBR were not important for the selectivity of PD168368. However, substitution of the 5th upper transmembrane domain (uTM5) of the NMBR by the comparable GRPR domains decreased the affinity 16-fold. When the reverse study was performed by substituting the uTM5 of NMBR into the GRPR, a 9-fold increase in affinity occurred. Each of the 4 amino acids that differed between NMBR and GRPR in the uTM5 region were exchanged, but only the substitution of Phe(220) for Tyr in the NMBR caused a decrease in affinity. When the reverse study was performed to attempt to demonstrate a gain of affinity in the GRPR, the substitution of Tyr(219) for Phe caused an increase in affinity. These results suggest that the hydroxyl group of Tyr(220) in uTM5 of NMBR plays a critical role for high selectivity of PD168368 for NMBR over GRPR. Receptor and ligand modeling suggests that the hydroxyl of the Tyr(220) interacts with nitrophenyl group of PD168368 likely primarily by hydrogen bonding. This result shows the selectivity of the peptoid PD168368, similar to that reported for numerous non-peptide analogues with other G protein-coupled receptors, is primarily dependent on interaction with transmembrane amino acids.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11013243     DOI: 10.1074/jbc.M006059200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

Review 1.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

Review 2.  Bombesin receptor subtype 3 as a potential target for obesity and diabetes.

Authors:  Nieves González; Paola Moreno; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2015-06-12       Impact factor: 6.902

3.  Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.

Authors:  Hirotsugu Uehara; Nieves González; Veronica Sancho; Samuel A Mantey; Bernardo Nuche-Berenguer; Tapas Pradhan; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2011-06-28       Impact factor: 3.750

4.  The molecular basis for high affinity of a universal ligand for human bombesin receptor (BnR) family members.

Authors:  Hirotsugu Uehara; Simon J Hocart; Nieves González; Samuel A Mantey; Tomoo Nakagawa; Tatsuro Katsuno; David H Coy; Robert T Jensen
Journal:  Biochem Pharmacol       Date:  2012-07-22       Impact factor: 5.858

5.  Development and Characterization of a Novel, High-Affinity, Specific, Radiolabeled Ligand for BRS-3 Receptors.

Authors:  Irene Ramos-Alvarez; Lingaku Lee; Samuel A Mantey; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2019-04-10       Impact factor: 4.030

6.  ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth.

Authors:  Terry W Moody; Samuel A Mantey; Paola Moreno; Taichi Nakamura; Enza Lacivita; Marcello Leopoldo; Robert T Jensen
Journal:  Peptides       Date:  2014-12-30       Impact factor: 3.750

7.  Molecular basis for the selectivity of the mammalian bombesin peptide, neuromedin B, for its receptor.

Authors:  Nieves González; Tomoo Nakagawa; Samuel A Mantey; Veronica Sancho; Hirotsugu Uehara; Tatsuro Katsuno; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2009-07-23       Impact factor: 4.030

8.  Molecular basis for high affinity and selectivity of peptide antagonist, Bantag-1, for the orphan BB3 receptor.

Authors:  Taichi Nakamura; Irene Ramos-Álvarez; Tatiana Iordanskaia; Paola Moreno; Samuel A Mantey; R T Jensen
Journal:  Biochem Pharmacol       Date:  2016-06-23       Impact factor: 5.858

9.  Molecular basis for agonist selectivity and activation of the orphan bombesin receptor subtype 3 receptor.

Authors:  Nieves Gonzalez; Simon J Hocart; Sergio Portal-Nuñez; Samuel A Mantey; Tomoo Nakagawa; Enrique Zudaire; David H Coy; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2007-11-15       Impact factor: 4.030

10.  Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.

Authors:  Nieves González; Samuel A Mantey; Tapas K Pradhan; Veronica Sancho; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2009-05-20       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.